Chengdu Shengnuo Biopharm Co., Ltd.—Semaglutide, Tirzepatide and Other API Industrialization Base Project Commences Construction Grandly

Project Background and Significance

As a wholly-owned subsidiary of Chengdu Shengnuo Bio-Technology Co., Ltd., Shengnuo Biopharm has been dedicated to the R&D and large-scale production of peptide drugs since its establishment in 2004. It is a leading enterprise in the domestic peptide API field. The company possesses over 50 key technologies for the large-scale production of marketed peptides domestically and internationally, with a single batch yield reaching kilogram scale, and has obtained U.S. FDA approval. It boasts full industrial chain capabilities from drug discovery to commercial production. This new industrialization base project will further solidify Shengnuo Bio's leading position in the peptide field and contribute to the development of the global peptide drug market.

Project Scale and Planning

The project will be constructed in two phases, with a total building area of 66,292.36 square meters and a floor area ratio of 1.2008. The first phase includes the construction of a boiler room and two Category C warehouses. The second phase plans to include eleven Category A workshops, Category A warehouses, utility stations, and supporting facilities. The project is located at No. 1, Industrial Avenue, Jinyuan Town, Dayi County, Chengdu, Sichuan Province, situated in the core area of the Dayi Economic Development Zone, offering a superior geographical location and complete industrial support.

Scientific Site Selection and Industrial Synergy

The Dayi Economic Development Zone, as a provincial-level key development zone, focuses on industries such as biomedicine and intelligent manufacturing, and has established a complete industrial chain and infrastructure. The project land complies with the overall land use planning, with no residential communities or environmental sensitive points in the surrounding area. It exhibits strong synergy with existing pharmaceutical and manufacturing enterprises in the zone, providing a solid foundation for the efficient progression of the project. The zone's roads, pipeline networks, landscaping, and other infrastructure are well-developed, and the convenient transportation further enhances the project's feasibility.

Future Outlook

Upon completion, the new base will further enhance Shengnuo Bio's industrialization capacity for peptide APIs, expand the global supply of core products such as cosmetic active peptides and Tirzepatide, while strengthening the layout of CDMO services and peptide preparation businesses. After reaching operational capacity, the project is expected to inject new momentum into regional economic development and drive the Chinese peptide pharmaceutical industry to a higher level.

Shengnuo Bio will take the commencement of this project as an opportunity to continuously deepen technological innovation and industrial chain integration, providing global clients with higher-quality peptide drug solutions.

Chengdu Shengnuo Biopharm Co., Ltd.
October 30, 2025